AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 262 min read

ArriVent BioPharma, Inc. Stock 12‑Month Price Target Raised to $24, Implies 14% Upside

Analysts raised ArriVent BioPharma's 12-month price target from $22.91 to $24, suggesting 14% upside. The consensus rating remains 'Buy' among 12 analysts. Forecasts range from $15 to $30 per share, according to estimates.

Original reporting
tradingview.com
Published Oct 26, 2026, 10:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ArriVent BioPharma, Inc. Stock 12‑Month Price Target Raised to $24, Implies 14% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The upward revision reflects analyst optimism but lacks fresh company‑specific catalysts.

02

Market read

Analyst target increase may prompt short‑term buying interest.

03

What to watch

No new clinical data disclosed; the raise is purely analyst opinion.

Relevance 6/10Novelty 7/10Timing: immediate

Background

ArriVent BioPharma is a clinical‑stage biotech focused on rare diseases.

Market effects

Sector

May lift sentiment in the biotech/clinical‑stage sector.

Regional

Limited to U.S. biotech investors.

Global

Minor, confined to ARVT shareholders.

Counterpoint

What could challenge this read

Target raises can be premature if upcoming trial data disappoints.

Key entities

  • company
    ArriVent BioPharma, Inc.

    Subject of the price‑target upgrade.

Read at source← All news

Related articles

OCT 27
$AVBPMedAI 9/10

ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.

finance.yahoo.com2 min
OCT 26
$AVBPHighAI 9/10

ArriVent BioPharma Reports 44.8% Response Rate for ARR-217 in Phase 1 CRC Data

ArriVent BioPharma reported Phase 1 data for ARR-217, showing a 44.8% response rate at 6 mg/kg in pretreated colorectal cancer patients. The disease control rate was 93.1% at this dose. At 4 mg/kg and higher, the response rate was 34.2% with a 91.8% disease control rate. Grade 3 or higher adverse events occurred in 30.1% of patients. The company plans to advance to Phase 1b dose optimization.

tradingview.com1 min
OCT 26
$AVBPMedAI 9/10

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 · 44.8% ORR at 6mg/kg dose in late-line CRC patients · ARR-217 was generally well-tolerated · ArriVent to host virtual webinar on Mo

SEC EDGAR 8-K2 min
OCT 25
$AVBPMedAI 8/10

ArriVent reports phase 1 data for cancer drug ARR-217

ArriVent BioPharma (AVBP) reported initial Phase 1 results for ARR-217, showing a 44.8% objective response rate at 6 mg/kg dose in pre-treated colorectal cancer patients. The study included 123 patients with gastrointestinal malignancies. ARR-217 is being developed with Lepu Biopharma. Phase 1b dose optimization is underway, with further data expected in 2027.

investing.com2 min
OCT 25
$AVBPMedAI 8/10

At one dose, an experimental cancer drug had a 44.8% response rate after earlier colorectal cancer treatments.

ArriVent BioPharma (AVBP) reported Phase 1 results for ARR-217, showing a 44.8% response rate in colorectal cancer patients at a 6mg/kg dose. The drug was generally well-tolerated. ArriVent plans a Phase 1b dose optimization study, with data expected in 2027. ARR-217 is a cadherin-17-targeting antibody-drug conjugate developed with Lepu Biopharma.

stocktitan.net2 min